Insider Profile · SEC Form 4 Activity · Trailing 90 Days
Orbimed Capital Gp Vii Llc
Over the trailing 90 days, Orbimed Capital Gp Vii Llc (10% Owner at Enliven Therapeutics, Inc.) traded $66.7M of stock (net selling $36.7M) across 2 companies, per 8 SEC Form 4 transactions.
- Role
- 10% Owner
- Window
- Trailing 90 days · 8 transactions · CIK 1760648
- Net activity
- −$36.7M ($15.0M bought · $51.7M sold)
By Company (Trailing 90 Days)
Transactions (8)
| Date | Symbol | Type | Shares | Value | Description |
|---|---|---|---|---|---|
| 2026-06-22 | ELVN | Sell | 787.0K | $35.7M | Open market or private sale |
| 2026-06-22 | ELVN | Sell | 24.8K | $1.1M | Open market or private sale |
| 2026-06-22 | ELVN | Sell | 46.8K | $2.1M | Open market or private sale |
| 2026-06-22 | ELVN | Sell | 1.5K | $66K | Open market or private sale |
| 2026-06-15 | ELVN | Sell | 272.3K | $12.3M | Open market or private sale |
| 2026-06-15 | ELVN | Sell | 9.1K | $409K | Open market or private sale |
| 2026-05-28 | QTTB | Buy | 1.2M | $10.0M | Open market or private purchase |
| 2026-05-28 | QTTB | Buy | 625.0K | $5.0M | Open market or private purchase |
Activity shown covers the trailing 90 days of SEC Form 4 filings. "Buy" and "sell" follow the SEC acquired/disposed codes and include compensation events (grants, option exercises, tax withholding) unless noted. Historical fact, not investment advice.
Follow Orbimed's next move
Real-time Form 4 alerts, insider track records, and cluster detection — matched to your watchlist.